Hospital perspective of shortages casts pharma earnings in bad light

Editor Ron Shinkman at sister publication FierceHealthFinance looks at drug shortages from the hospital exec's perspective and doesn't especially like what he sees. He finds that some shortages are caused by factory shutdowns. But unlike most other businesses in which shutdowns can lead to devastating write-offs, he instead finds companies revising operating and net income upward. Among his examples: Daiichi Sankyo's ($4568) American Regent, Hospira ($HSP), Boehringer Ingelheim's Bedford Labs and Bristol-Myers Squibb ($BMY). Editorial

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.